Analysts at Peel Hunt Reconfirmed their “Hold” rating for Babcock International Group PLC (LON:BAB) with GBX 785.00 Target; Profile of 9 Analysts Covering Akebia Therapeutics, Inc. (AKBA)

London: In a note made public on Tuesday, 6 February, Peel Hunt reaffirmed their “Hold” rating on shares of Babcock International Group PLC (LON:BAB). They currently have a GBX 785.00 target on the firm. Peel Hunt’s target would suggest a potential upside of 22.94% from the company’s previous stock close.

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 24 analyst reports since August 13, 2015 according to SRatingsIntel. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm has “Equal Weight” rating by Morgan Stanley given on Thursday, August 13. Mizuho initiated the stock with “Buy” rating in Wednesday, October 4 report. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Buy” rating by H.C. Wainwright on Tuesday, December 27. H.C. Wainwright maintained it with “Buy” rating and $2400 target in Wednesday, August 9 report. On Tuesday, December 15 the stock rating was maintained by H.C. Wainwright with “Buy”. Aegis Capital maintained the shares of AKBA in report on Friday, June 30 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Tuesday, March 15. The company was maintained on Thursday, August 13 by Brean Capital. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) has “Buy” rating given on Thursday, December 7 by BTIG Research. See Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings:

18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
04/10/2017 Broker: Mizuho Rating: Buy New Target: $24.0 Initiate
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $17 Initiates Coverage On
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $668.39 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Since August 15, 2017, it had 0 buys, and 5 insider sales for $377,477 activity. Dahan Michel also sold $27,457 worth of Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares. Nash Duane had sold 1,188 shares worth $23,332. Hadas Nicole R. sold 7,803 shares worth $155,188.

The stock decreased 2.88% or $0.42 during the last trading session, reaching $14.14. About 234,500 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 76.80% since February 6, 2017 and is uptrending. It has outperformed by 60.10% the S&P500.

Investors sentiment decreased to 2.23 in Q3 2017. Its down 0.02, from 2.25 in 2017Q2. It turned negative, as 17 investors sold Akebia Therapeutics, Inc. shares while 14 reduced holdings. 25 funds opened positions while 44 raised stakes. 28.78 million shares or 10.48% more from 26.05 million shares in 2017Q2 were reported. 71,586 were accumulated by California State Teachers Retirement Sys. Acadian Asset Mgmt Ltd Liability Company has 728,229 shares for 0.06% of their portfolio. Renaissance Techs owns 1.42 million shares. Rhumbline Advisers reported 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Fifth Third Bank reported 6,600 shares. Numeric Invsts Ltd Liability holds 0.06% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 377,074 shares. Dimensional Fund Advsr Ltd Partnership, a Texas-based fund reported 35,572 shares. 4,329 are owned by Bnp Paribas Arbitrage Sa. Dafna Ltd Company holds 135,738 shares or 1.66% of its portfolio. Legal & General Grp Public Limited Company reported 0% stake. Cwm Limited Liability Company stated it has 31 shares or 0% of all its holdings. Creative Planning invested in 10,650 shares. Citigroup holds 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 27,301 shares. Panagora Asset Mngmt Inc stated it has 30,126 shares. Mutual Of America Cap Ltd Liability Company holds 0.04% or 111,400 shares.

Among 19 analysts covering Babcock International Group PLC (LON:BAB), 13 have Buy rating, 1 Sell and 5 Hold. Therefore 68% are positive. Babcock International Group PLC has GBX 1500 highest and GBX 660 lowest target. GBX 1067.76’s average target is 66.84% above currents GBX 640 stock price. Babcock International Group PLC had 178 analyst reports since July 27, 2015 according to SRatingsIntel. JP Morgan maintained the stock with “Overweight” rating in Wednesday, November 22 report. Liberum Capital maintained the stock with “Sell” rating in Monday, February 1 report. The firm earned “Neutral” rating on Monday, March 13 by BNP Paribas. The stock of Babcock International Group plc (LON:BAB) earned “Neutral” rating by BNP Paribas on Monday, November 7. BNP Paribas maintained Babcock International Group plc (LON:BAB) rating on Monday, February 27. BNP Paribas has “Neutral” rating and GBX 1020 target. The rating was maintained by Shore Capital on Thursday, September 29 with “Buy”. The stock of Babcock International Group plc (LON:BAB) earned “Underperform” rating by BNP Paribas on Wednesday, November 25. Goldman Sachs maintained Babcock International Group plc (LON:BAB) rating on Wednesday, November 25. Goldman Sachs has “Buy” rating and GBX 1302 target. The rating was maintained by Peel Hunt on Wednesday, January 3 with “Hold”. The firm has “Hold” rating by Peel Hunt given on Tuesday, January 23.

The stock decreased 1.93% or GBX 12.6 during the last trading session, reaching GBX 640. About 1.23M shares traded. Babcock International Group plc (LON:BAB) has 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.

Babcock International Group PLC, together with its subsidiaries, provides engineering support services for defense, marine, aviation, and nuclear sectors. The company has market cap of 3.23 billion GBP. It operates through Marine and Technology, Defence and Security, Support Services, and International divisions. It has a 10.02 P/E ratio. The firm delivers through-life marine engineering services ranging from supporting naval fleets, commercial marine, engineering consultancy, weapons handling, equipment support, intelligence and cyber-security, and technical training to defense and civil customers.